NCT03717181No Longer Available不适用
Expanded Access Use of Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Palladio Biosciences1 个研究点 分布在 1 个国家开始时间: 2018年10月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 15 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of understanding the written informed consent/assent.
- •Provides signed and witnessed written informed consent/assent, and agrees to comply with protocol requirements and study-related procedures.
- •At least 15 years of age at the time of Screening.
- •Subject has been diagnosed with ADPKD by modified Ravine criteria:
- •If the subject has a family history of ADPKD, a minimum of 3 cysts per kidney by sonography or 5 cysts by computerized tomography or MRI; or
- •If the subject does not have a family history of ADPKD, a minimum of 10 cysts per kidney by any radiologic method and exclusion of other cystic kidney diseases.
- •Considered by the Investigator to be in good health relative to underlying CKD status and clinically stable with respect to underlying CKD, based on medical evaluation that includes medical and surgical history, as well as a complete physical examination including vital signs, ECG, and laboratory test results.
排除标准
- •Has a known sensitivity or idiosyncratic reaction to any compound present in lixivaptan or any compound listed as being present in the formulation.
- •Is pregnant or breast feeding.
- •Has taken any investigational drug or used an investigational device within 30 days or 5 half-lives, whichever is longer, prior to Screening.
- •Has taken tolvaptan, conivaptan, somatostatin analogs (e.g. lanreotide, pasireotide, octreotide, etc.), mTOR kinase inhibitors (e.g. everolimus, sirolimus, etc.), or oral or intravenous antibiotics within 30 days or 5 half-lives, whichever is longer, prior to Day
- •Has a history of testing positive for hepatitis B surface antigen, hepatitis C, or human immunodeficiency virus (HIV).
- •Consumes grapefruit or Seville oranges (or their juices, or foods containing their extract) from 7 days prior to the first dose of study medication and until after the final dose.
- •Has clinically significant liver disease, or clinically significant liver function abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline.
- •Has any clinically significant laboratory abnormalities or concomitant conditions other than ADPKD (including treatment for such conditions) that, in the opinion of the Investigator, could either interfere with the study drug or pose an unacceptable risk to the subject.
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Study of Tamibarotene in Patients With ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)NCT06289998Rege Nephro Co., Ltd.70
Enrolling By Invitation
2 期
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseChronic Kidney DiseasesAutosomal Dominant Polycystic Kidney DiseaseNCT05870007Taipei Medical University Shuang Ho Hospital30
已完成
2 期
Tolvaptan-Octreotide LAR Combination in ADPKDAutosomal Dominant Polycystic Kidney DiseaseNCT03541447Mario Negri Institute for Pharmacological Research20
Unknown
不适用
Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis PatientsChronic Kidney DiseaseNCT01509027Universitaire Ziekenhuizen KU Leuven150
Unknown
3 期
Study of Lanreotide to Treat Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)NCT01616927University Medical Center Groningen300